{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:00:09Z","timestamp":1792285209330,"version":"4.4.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clozapine remains the only drug treatment likely to benefit patients with treatment resistant schizophrenia. Its use is complicated by an increased risk of neutropenia and so there are stringent monitoring requirements and restrictions in those with previous neutropenia from any cause or from clozapine in particular. Despite these difficulties clozapine may yet be used following neutropenia, albeit with caution. Having had involvement with 14 cases of clozapine use in these circumstances we set out our approach to the assessment of risks and benefits, risk mitigation and monitoring with a practical guide.<\/jats:p>","DOI":"10.1186\/s12888-020-02592-2","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T12:02:43Z","timestamp":1591358563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide"],"prefix":"10.1186","volume":"20","author":[{"given":"Edward","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"2","key":"2592_CR1","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1097\/MJT.0000000000000715","volume":"25","author":"P Manu","year":"2018","unstructured":"Manu P, Lapitskaya Y, Shaikh A, Nielsen J. Clozapine Rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther. 2018;25(2):e218\u2013e23.","journal-title":"Am J Ther"},{"issue":"1","key":"2592_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1192\/bjb.2018.61","volume":"43","author":"A Till","year":"2019","unstructured":"Till A, Selwood J, Silva E. The assertive approach to clozapine: nasogastric administration. BJPsych Bull. 2019;43(1):21\u20136.","journal-title":"BJPsych Bull"},{"issue":"1","key":"2592_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12888-018-2001-7","volume":"19","author":"A Till","year":"2019","unstructured":"Till A, Silva E. A case report of the successful administration of clozapine in the face of myocardial infarction, pulmonary embolism and hyperlipidaemia resulting in the termination of long-term seclusion. BMC Psychiatry. 2019;19(1):37.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"2592_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1192\/apt.bp.116.016147","volume":"23","author":"E Silva","year":"2017","unstructured":"Silva E, Till A, Adshead G. Ethical dilemmas in psychiatry: when teams disagree. BJPsych Advances. 2017;23(4):231\u20139.","journal-title":"BJPsych Advances"},{"key":"2592_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1192\/bjp.187.3.248","volume":"187","author":"W Gaebel","year":"2005","unstructured":"Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005;187:248\u201355.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"2592_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318\u201378.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"2592_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF00606410","volume":"11","author":"B Anderman","year":"1977","unstructured":"Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to august 1976. Eur J Clin Pharmacol. 1977;11(3):199\u2013201.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2592_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0957154X07070335","volume":"18","author":"J Crilly","year":"2007","unstructured":"Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39\u201360.","journal-title":"Hist Psychiatry"},{"issue":"2","key":"2592_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.12898","volume":"138","author":"N Myles","year":"2018","unstructured":"Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138(2):101\u20139.","journal-title":"Acta Psychiatr Scand"},{"key":"2592_CR10","unstructured":"Interactive drug analysis profile: Clozapine [Internet]. MHRA. 2019. Available from: https:\/\/info.mhra.gov.uk\/drug-analysis-profiles\/dap.html?drug=.\/UK_EXTERNAL\/NONCOMBINED\/UK_NON_000299949199.zip&agency=MHRA."},{"issue":"2","key":"2592_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","volume":"30","author":"J Nielsen","year":"2016","unstructured":"Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149\u201361.","journal-title":"CNS Drugs"},{"issue":"5","key":"2592_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/YIC.0000000000000258","volume":"34","author":"E Whiskey","year":"2019","unstructured":"Whiskey E, Dzahini O, Ramsay R, O\u2019Flynn D, Mijovic A, Gaughran F, et al. Need to bleed? Clozapine haematological monitoring approaches a time for change. Int Clin Psychopharmacol. 2019;34(5):264\u20138..","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"2592_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/acps.12673","volume":"135","author":"MI Jakobsen","year":"2017","unstructured":"Jakobsen MI, Larsen JR, Svensson CK, Johansen SS, Linnet K, Nielsen J, et al. The significance of sampling time in therapeutic drug monitoring of clozapine. Acta Psychiatr Scand. 2017;135(2):159\u201369.","journal-title":"Acta Psychiatr Scand"},{"issue":"S1","key":"2592_CR14","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/hup.917","volume":"23","author":"RJ Flanagan","year":"2008","unstructured":"Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2008;23(S1):S27\u201341.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"9237","key":"2592_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet."},{"issue":"1\u20133","key":"2592_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.schres.2012.06.020","volume":"140","author":"R Roge","year":"2012","unstructured":"Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012;140(1\u20133):204\u201313.","journal-title":"Schizophr Res"},{"issue":"15","key":"2592_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.2217\/pgs.13.182","volume":"14","author":"BW Spencer","year":"2013","unstructured":"Spencer BW, Prainsack B, Rujescu D, Giegling I, Collier DA, Gaughran F, et al. Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine. Pharmacogenomics. 2013;14(15):1907\u201314.","journal-title":"Pharmacogenomics."},{"key":"2592_CR18","doi-asserted-by":"publisher","unstructured":"Sriretnakumar V, Huang E, M\u00fcller DJ. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. Expert Opin Drug Metab Toxicol. 2015;11(11):1709-31. https:\/\/doi.org\/10.1517\/17425255.2015.1075003.","DOI":"10.1517\/17425255.2015.1075003"},{"key":"2592_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/mp.2017.214","volume":"23","author":"SE Legge","year":"2017","unstructured":"Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry. 2017;23:162.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"2592_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/pgs-2018-0188","volume":"20","author":"SE Legge","year":"2019","unstructured":"Legge SE, Walters JTR. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics. 2019;20(4):279\u201390.","journal-title":"Pharmacogenomics."},{"issue":"5","key":"2592_CR21","first-page":"461","volume":"15","author":"M Verbelen","year":"2015","unstructured":"Verbelen M, Collier DA, Cohen D, MacCabe JH, Lewis CM. Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis. Pharm J. 2015;15(5):461\u20136.","journal-title":"Pharm J"},{"issue":"2","key":"2592_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2165\/00023210-199707020-00005","volume":"7","author":"M Pirmohamed","year":"1997","unstructured":"Pirmohamed M, Park K. Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development. CNS Drugs. 1997;7(2):139\u201358.","journal-title":"CNS Drugs"},{"key":"2592_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1192\/bjp.188.3.255","volume":"188","author":"LR Dunk","year":"2006","unstructured":"Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry. 2006;188:255\u201363.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"2592_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/JCP.0000000000000512","volume":"36","author":"CR Prokopez","year":"2016","unstructured":"Prokopez CR, Armesto AR, Gil Aguer MF, Balda MV, Papale RM, Bignone IM, et al. Clozapine Rechallenge after neutropenia or leucopenia. J Clin Psychopharmacol. 2016;36(4):377\u201380.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"2592_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YCO.0000000000000159","volume":"28","author":"S Miyamoto","year":"2015","unstructured":"Miyamoto S, Jarskog LF, Fleischhacker WW. Schizophrenia: when clozapine fails. Curr Opin Psychiatry. 2015;28(3):243\u20138.","journal-title":"Curr Opin Psychiatry"},{"key":"2592_CR26","volume-title":"Clozapine handbook","author":"S Bleakley","year":"2013","unstructured":"Bleakley S, Taylor D. Clozapine handbook. Dorsington: Lloyd-Reinhold Communications LLP; 2013."},{"key":"2592_CR27","volume-title":"ECDU assessment manual for psychopharmacology-revised","author":"GW The","year":"1976","unstructured":"The GW, Clinical Global Impression Scale. ECDU assessment manual for psychopharmacology-revised. Rockville: US Dept. of Health Education and Welfare; 1976. p. 218-22."},{"issue":"5","key":"2592_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385\u201392.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"2592_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2045125318781475","volume":"8","author":"PM Haddad","year":"2018","unstructured":"Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"2","key":"2592_CR30","first-page":"93","volume":"31","author":"O Agid","year":"2006","unstructured":"Agid O, Seeman P, Kapur S. The \"delayed onset\" of antipsychotic action--an idea whose time has come and gone. J Psychiatry Neurosci. 2006;31(2):93\u2013100.","journal-title":"J Psychiatry Neurosci"},{"issue":"7","key":"2592_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00003088-200342070-00001","volume":"42","author":"P Schulte","year":"2003","unstructured":"Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42(7):607\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2592_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1192\/bjp.bp.110.083907","volume":"199","author":"T Suzuki","year":"2011","unstructured":"Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, et al. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry. 2011;199(4):275\u201380.","journal-title":"Br J Psychiatry"},{"issue":"3 Suppl 2","key":"2592_CR33","first-page":"S19","volume":"60","author":"WG Honer","year":"2015","unstructured":"Honer WG, Jones AA, Thornton AE, Barr AM, Procyshyn RM, Vila-Rodriguez F. Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia. Can J Psychiatr. 2015;60(3 Suppl 2):S19\u201325.","journal-title":"Can J Psychiatr"},{"issue":"9","key":"2592_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1017\/S146114571100201X","volume":"15","author":"C Frogley","year":"2012","unstructured":"Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15(9):1351\u201371.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"2592_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-012-2922-7","volume":"225","author":"G Remington","year":"2013","unstructured":"Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology. 2013;225(3):505\u201318.","journal-title":"Psychopharmacology"},{"key":"2592_CR36","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.blre.2019.06.003","volume":"37","author":"SA Atallah-Yunes","year":"2019","unstructured":"Atallah-Yunes SA, Ready A, Newburger PE. Benign ethnic neutropenia. Blood Rev. 2019;37:100586.","journal-title":"Blood Rev"},{"issue":"8","key":"2592_CR37","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood-2014-02-482612","volume":"124","author":"C Gibson","year":"2014","unstructured":"Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood. 2014;124(8):1251\u20138.","journal-title":"Blood."},{"issue":"3","key":"2592_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41380-018-0335-7","volume":"24","author":"SE Legge","year":"2019","unstructured":"Legge SE, Pardinas AF, Helthuis M, Jansen JA, Jollie K, Knapper S, et al. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Mol Psychiatry. 2019;24(3):328\u201337.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"2592_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ajh.10295","volume":"72","author":"TP van Staa","year":"2003","unstructured":"van Staa TP, Boulton F, Cooper C, Hagenbeek A, Inskip H, Leufkens HG. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol. 2003;72(4):248\u201354.","journal-title":"Am J Hematol"},{"issue":"8","key":"2592_CR40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eurpsy.2004.09.007","volume":"19","author":"MJ Imbarlina","year":"2004","unstructured":"Imbarlina MJ, Sarkar S, Marwah S, Parepally H, Johnston PR, Brar JS, et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur Psychiatry. 2004;19(8):506\u20139.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"2592_CR41","first-page":"122","volume":"36","author":"R Durst","year":"1999","unstructured":"Durst R, Teitelbaum A, Katz G, Knobler HY. Withdrawal from clozapine: the \"rebound phenomenon\". Isr J Psychiatry Relat Sci. 1999;36(2):122\u20138.","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"6","key":"2592_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijlp.2007.09.003","volume":"30","author":"PF Schulte","year":"2007","unstructured":"Schulte PF, Stienen JJ, Bogers J, Cohen D, van Dijk D, Lionarons WH, et al. Compulsory treatment with clozapine: a retrospective long-term cohort study. Int J Law Psychiatry. 2007;30(6):539\u201345.","journal-title":"Int J Law Psychiatry"},{"key":"2592_CR43","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/ncomms5757","volume":"5","author":"JI Goldstein","year":"2014","unstructured":"Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.","journal-title":"Nat Commun"},{"issue":"1","key":"2592_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3371\/CSRP.5.1.4","volume":"5","author":"JR McKee","year":"2011","unstructured":"McKee JR, Wall T, Owensby J. Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients. Clin Schizophr Relat Psychoses. 2011;5(1):26\u201332.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"2 Pt 2","key":"2592_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/15622970902806132","volume":"11","author":"S Ferrea","year":"2010","unstructured":"Ferrea S, Fehsel K, Cordes J, Luckhaus C. Circadian rhythm of neutrophil counts and granulocyte macrophage-colony stimulating factor (GM-CSF) under clozapine treatment: a case report. World J Biol Psychiatry. 2010;11(2 Pt 2):511\u20133.","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"2592_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00007256-198806060-00002","volume":"6","author":"DA McCarthy","year":"1988","unstructured":"McCarthy DA, Dale MM. The Leucocytosis of exercise. Sports Med. 1988;6(6):333\u201363.","journal-title":"Sports Med"},{"key":"2592_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.exphem.2018.10.007","volume":"69","author":"JTD Souto Filho","year":"2019","unstructured":"Souto Filho JTD, Portugal RD, Nucci M. Effect of circadian variation on neutrophil mobilization to the peripheral blood in benign constitutional neutropenia. Exp Hematol. 2019;69:22\u20136.","journal-title":"Exp Hematol"},{"key":"2592_CR48","doi-asserted-by":"publisher","first-page":"e5368","DOI":"10.1136\/bmj.e5368","volume":"345","author":"R Phillips","year":"2012","unstructured":"Phillips R, Hancock B, Graham J, Bromham N, Jin H, Berendse S. Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance. Bmj. 2012;345:e5368.","journal-title":"Bmj."},{"issue":"3","key":"2592_CR49","first-page":"153","volume":"1","author":"PD Wickramanayake","year":"1995","unstructured":"Wickramanayake PD, Scheid C, Josting A, Katay I, Schulz A, Diehl V. Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. Eur J Med Res. 1995;1(3):153\u20136.","journal-title":"Eur J Med Res"},{"issue":"7","key":"2592_CR50","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1537-2995.2008.01694.x","volume":"48","author":"D Pamphilon","year":"2008","unstructured":"Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion. 2008;48(7):1495\u2013501.","journal-title":"Transfusion."},{"issue":"3","key":"2592_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.seminhematol.2013.06.010","volume":"50","author":"PE Newburger","year":"2013","unstructured":"Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013;50(3):198\u2013206.","journal-title":"Semin Hematol"},{"issue":"3","key":"2592_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00004850-199805000-00008","volume":"13","author":"P Blier","year":"1998","unstructured":"Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia\/agranulocytosis. Int Clin Psychopharmacol. 1998;13(3):137\u201340.","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"2592_CR53","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1177\/0269881112450782","volume":"26","author":"BW Spencer","year":"2012","unstructured":"Spencer BW, Williams HR, Gee SH, Whiskey E, Rodrigues JP, Mijovic A, et al. Granulocyte Colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic Neutropaenia (BEN): a case report. J Psychopharmacol. 2012;26(9):1280\u20132.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"2592_CR54","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-2141.1992.tb04574.x","volume":"80","author":"R Weide","year":"1992","unstructured":"Weide R, Koppler H, Heymanns J, Pfluger KH, Havemann K. Successful treatment of clozapine induced agranulocytosis with granulocyte-colony stimulating factor (G-CSF). Br J Haematol. 1992;80(4):557\u20139.","journal-title":"Br J Haematol"},{"key":"2592_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1192\/bjp.172.1.82","volume":"172","author":"B Sperner-Unterweger","year":"1998","unstructured":"Sperner-Unterweger B, Czeipek I, Gaggl S, Geissler D, Spiel G, Fleischhacker WW. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine. Br J Psychiatry. 1998;172:82\u20134.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"2592_CR56","first-page":"1503","volume":"153","author":"D Pasquale","year":"1996","unstructured":"Pasquale D, Newton M, Goss JB, Simor G, Lesieur S. Granulocyte colony-stimulating factor treatment of clozapine-induced agranulocytosis. Am J Psychiatry. 1996;153(11):1503\u20134.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2592_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2796.1993.tb00789.x","volume":"234","author":"H Nielsen","year":"1993","unstructured":"Nielsen H. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis. J Intern Med. 1993;234(5):529\u201331.","journal-title":"J Intern Med"},{"issue":"6","key":"2592_CR58","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/SMJ.0b013e318172f6c6","volume":"101","author":"TG Majczenko","year":"2008","unstructured":"Majczenko TG, Stewart JT. Failure of filgrastim to prevent severe clozapine-induced agranulocytosis. South Med J. 2008;101(6):639\u201340.","journal-title":"South Med J"},{"issue":"5","key":"2592_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/2045125313476877","volume":"3","author":"AA Khan","year":"2013","unstructured":"Khan AA, Harvey J, Sengupta S. Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia. Ther Adv Psychopharmacol. 2013;3(5):266\u201371.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"2","key":"2592_CR60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1176\/appi.ajp.2008.08081295","volume":"166","author":"G Joffe","year":"2009","unstructured":"Joffe G, Eskelinen S, Sailas E. Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia\/agranulocytosis. Am J Psychiatry. 2009;166(2):236.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2592_CR61","first-page":"81","volume":"21","author":"P Heinz","year":"1994","unstructured":"Heinz P, Muller H, Bauer M. Treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor G-CSF. Psychiatr Prax. 1994;21(2):81.","journal-title":"Psychiatr Prax"},{"issue":"9","key":"2592_CR62","first-page":"401","volume":"55","author":"G Gullion","year":"1994","unstructured":"Gullion G, Yeh HS. Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. J Clin Psychiatry. 1994;55(9):401\u20135.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl B","key":"2592_CR63","first-page":"139","volume":"55","author":"SL Gerson","year":"1994","unstructured":"Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry. 1994;55(Suppl B):139\u201342.","journal-title":"J Clin Psychiatry"},{"issue":"8827","key":"2592_CR64","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/0140-6736(92)93116-5","volume":"340","author":"SL Gerson","year":"1992","unstructured":"Gerson SL, Gullion G, Yeh HS, Masor C. Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis. Lancet. 1992;340(8827):1097.","journal-title":"Lancet."},{"issue":"11","key":"2592_CR65","doi-asserted-by":"publisher","first-page":"e1410","DOI":"10.4088\/JCP.14m09326","volume":"76","author":"N Meyer","year":"2015","unstructured":"Meyer N, Gee S, Whiskey E, Taylor D, Mijovic A, Gaughran F, et al. Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry. 2015;76(11):e1410\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2592_CR66","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/JCP.0000000000000767","volume":"37","author":"J Lally","year":"2017","unstructured":"Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, et al. The use of granulocyte Colony-stimulating factor in clozapine Rechallenge: a systematic review. J Clin Psychopharmacol. 2017;37(5):600\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2592_CR67","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/JCP.0000000000000715","volume":"37","author":"J Lally","year":"2017","unstructured":"Lally J, Malik S, Whiskey E, Taylor DM, Gaughran FP, Krivoy A, et al. Clozapine-associated Agranulocytosis treatment with granulocyte Colony-stimulating factor\/granulocyte-macrophage Colony-stimulating factor: a systematic review. J Clin Psychopharmacol. 2017;37(4):441\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2592_CR68","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1046\/j.1537-2995.2001.41020184.x","volume":"41","author":"U Platzbecker","year":"2001","unstructured":"Platzbecker U, Prange-Krex G, Bornhauser M, Koch R, Soucek S, Aikele P, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion. 2001;41(2):184\u20139.","journal-title":"Transfusion."},{"issue":"21","key":"2592_CR69","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood.V116.21.1484.1484","volume":"116","author":"LA DiMeglio","year":"2010","unstructured":"DiMeglio LA, Bolyard AA, Marrero TM, Alter BP, Bonilla MA, Boxer LA, et al. The Risk of Low Bone Mineral Density with Long-Term G-CSF Therapy for Severe Chronic Neutropenia. Blood. 2010;116(21):1484.","journal-title":"Blood"},{"issue":"3","key":"2592_CR70","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/bmt.2014.278","volume":"50","author":"BE Shaw","year":"2015","unstructured":"Shaw BE, Confer DL, Hwang W, Pulsipher MA. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplant. 2015;50(3):334.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2592_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1189\/jlb.0608388","volume":"85","author":"D Focosi","year":"2009","unstructured":"Focosi D, Azzar\u00e0 A, Kast RE, Carulli G, Petrini M. Lithium and hematology: established and proposed uses. J Leukoc Biol. 2009;85(1):20\u20138.","journal-title":"J Leukoc Biol"},{"issue":"2\u20133","key":"2592_CR72","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","volume":"134","author":"P Manu","year":"2012","unstructured":"Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2012;134(2\u20133):180\u20136.","journal-title":"Schizophr Res"},{"key":"2592_CR73","doi-asserted-by":"crossref","unstructured":"Boazak M, Goldsmith DR, Cotes RO. Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky. Prim Care Companion CNS Disord. Author manuscript; avaliable in PMC 2019 Nov 29.","DOI":"10.4088\/PCC.18l02282"},{"issue":"8761","key":"2592_CR74","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/0140-6736(91)90410-Q","volume":"338","author":"SL Gerson","year":"1991","unstructured":"Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx JJ Jr, Meltzer H. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet. 1991;338(8761):262\u20133.","journal-title":"Lancet."},{"issue":"3","key":"2592_CR75","first-page":"223","volume":"23","author":"JG Small","year":"2003","unstructured":"Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 2003;23(3):223\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2592_CR76","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3371\/CSRP.4.2.5","volume":"4","author":"S Nykiel","year":"2010","unstructured":"Nykiel S, Henderson D, Bhide G, Freudenreich O. Lithium to allow clozapine prescribing in benign ethnic neutropenia. Clin Schizophr Relat Psychoses. 2010;4(2):138\u201340.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"5","key":"2592_CR77","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4088\/JCP.v67n0509","volume":"67","author":"RA Kanaan","year":"2006","unstructured":"Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry. 2006;67(5):756\u201360.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2592_CR78","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/026988110101500409","volume":"15","author":"SM Dursun","year":"2001","unstructured":"Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol. 2001;15(4):297\u2013301.","journal-title":"J Psychopharmacol"},{"key":"2592_CR79","doi-asserted-by":"crossref","unstructured":"Boazak M, Kahn B, Cox L, Ragazino J, Goldsmith DR, Cotes RO. Re-titration rates after clozapine-induced neutropenia or agranulocytosis: a case report and literature review. Clin Schizophr Relat Psychoses. Author Manuscript; avaliable in PMC 2019 Dec 29.","DOI":"10.3371\/CSRP.BOKA.061518"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02592-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:38:07Z","timestamp":1622849887000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02592-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2592"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02592-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"19 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nil, ICMJE conflicts of interest forms have been completed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}